MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fdmed.2026.1868023

Медицинская библиотека · Frontiers in dental medicine · 2026

Glucosamine supplementation in the treatment of temporomandibular joint disorders: a systematic review and meta-analysis.

Calzada-Gonzales Nancy, Aguirre-Ipenza Rubén, Serna-Alarcón Victor, Valeriano-Mamani Jordan, Mendoza-Torres Rocio, Hueda-Zavaleta Miguel, Taype-Rondan Alvaro, Brañez-Condorena Ana, Alarcon-Ruiz Christoper A

СтатьяСистематический обзорПеревод в очереди

Аннотация

BACKGROUND

Glucosamine has been proposed as a therapeutic option for temporomandibular disorders (TMD), particularly temporomandibular joint osteoarthritis (TMJ OA), but its effectiveness and safety remain uncertain.

OBJECTIVE

To evaluate the benefits and harms of oral glucosamine supplementation in patients with TMJ OA and other/unspecified TMD.

METHODS

A systematic review was conducted in PubMed/MEDLINE, CENTRAL, Scopus, and Embase through October 8, 2025. Randomized controlled trials (RCTs) evaluating oral glucosamine supplementation in patients with any type of TMD, including TMJ OA, were selected. Meta-analyses were performed using random-effects models, and the GRADE methodology was applied to assess the certainty of the evidence.

RESULTS

Seven RCTs were included. In patients with TMJ OA, compared with placebo, glucosamine may not result in a clinically important reduction in pain at ≤3 months (MD -1.58 mm; 95% CI -5.98 to 2.83; low certainty) and probably does not provide a clinically important reduction at 6 months despite statistical significance (MD -7.02 mm; 95% CI -11.95 to -2.09; moderate certainty). Glucosamine improved quality of life at 12 months (MD -4.14; 95% CI -6.41 to -1.87; high certainty). Compared with active controls, the effect on pain was uncertain, although quality of life may improve at 3 months. In patients with other/unspecified TMD, glucosamine may not meaningfully reduce pain but may increase maximum pain-free mandibular opening at 3 months. Evidence regarding adverse and serious adverse events was very uncertain across comparisons.

CONCLUSION

Oral glucosamine does not provide a clinically important reduction in pain in TMJ OA or other/unspecified TMD but may improve quality of life in TMJ OA. Evidence for functional outcomes and adverse events remains uncertain, highlighting the need for high-quality randomized trials.

SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024531131, identifier CRD42024531131.

Для цитирования: Calzada-Gonzales Nancy, Aguirre-Ipenza Rubén, Serna-Alarcón Victor, Valeriano-Mamani Jordan, Mendoza-Torres Rocio, Hueda-Zavaleta Miguel, Taype-Rondan Alvaro, Brañez-Condorena Ana, Alarcon-Ruiz Christoper A. Glucosamine supplementation in the treatment of temporomandibular joint disorders: a systematic review and meta-analysis.. Frontiers in dental medicine. 2026. DOI: 10.3389/fdmed.2026.1868023.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.